

KraneShares Global Humanoid Robotics and Physical AI Index UCITS ETF

KraneShares Global Humanoid Robotics and Physical AI Index UCITS ETF is a sub fund of KraneShares ICAV (the "ICAV"). The ICAV is authorised as a UCITS in Ireland and regulated by the Central Bank of Ireland.

This is a marketing communication. Please refer to the prospectus of the UCITS, the KIID and the PRIIP before making any final investment decisions. The tax treatment depends on the individual circumstances of each client and may be subject to change in the future.

Investment Strategy:

KOID seeks to track the MerQube Global Humanoid Robotics and Physical AI Index, which is designed to capture the performance of companies engaged in humanoid and embodied intelligence-related business.

Humanoid & Embodied Intelligence Highlights:

- Market Growth:** The Morgan Stanley Global Humanoid Model projects there could be 1 billion humanoids and \$5 trillion in annual revenue by 2050.¹ Goldman Sachs is also projecting significant market expansion, forecasting a compound annual growth rate (CAGR) of 41.8% over the next decade.²
- Technological Convergence Driving Innovation:** Breakthroughs in artificial intelligence (AI), machine learning, and advanced materials are revolutionizing humanoid capabilities.
- Expanding Applications Across Multiple Industries:** Humanoid robots are addressing critical challenges in sectors like manufacturing, healthcare, logistics, and elder care.

KOID Features:

- Invest across the full spectrum of the humanoid ecosystem, including the "brain" (semiconductors & technology), the "body" (actuation & mechanical systems, sensing & perception, critical materials), and humanoid "integrators" & manufacturing companies.
- Global exposure to companies based primarily in the United States, China, and Japan included in the information technology, industrial, and consumer discretionary sectors.

1. Data from "Humanoids: 1bn Robots and \$5tn Revenues by 2050, China is in Pole Position," Morgan Stanley Research, retrieved 31/Mar/2026.
2. Data from "The global market for humanoid robots could reach \$38 billion by 2035," Goldman Sachs Research, retrieved 31/Mar/2026.

Fund Details	Data as of 31/Jul/2026
Primary SEDOL	BVBBGT9
Primary ISIN	IE00006Z73N7
Inception Date	09/Oct/2025
Total Annual Fund Operating Expense	0.69%
Distribution Frequency	Accumulating
Index Name	MerQube Global Humanoid Robotics and Physical AI Index
Methodology	Physical Replication
Net Assets	\$90,679,105
Number of Holdings	59
UK Reporting Fund Status	Reporting Fund
Investment Structure	UCITS
Base Currency	USD

Top 10 Holdings as of 31/Jul/2026 Holdings are subject to change.	Ticker	%
HEXAGON AB-B SHS	HEXAB	2.57
HORIZON ROBOTICS INC	9660	2.49
MAGNA INTERNATIONAL INC	MG	2.32
MONOLITHIC POWER SYSTEMS INC	MPWR	2.31
SENSATA TECHNOLOGIES HOLDING	ST	2.24
TERADYNE INC	TER	2.24
TE CONNECTIVITY PLC	TEL	2.23
RAINBOW ROBOTICS	277810	2.22
SYMBOTIC INC	SYM	2.20
TELEDYNE TECHNOLOGIES INC	TDY	2.18

KOID Performance History:

	Cumulative % Data as of month end: 31/Jul/2026				Average Annualized % Data as of month end: 31/Jul/2026				Cumulative % Data as of quarter end: 30/Jun/2026			
	1 Mo	3 Mo	6 Mo	Since Inception	1 Yr	3 Yr	5 Yr	Since Inception	1 Yr	3 Yr	5 Yr	Since Inception
Fund NAV	-10.14%	-1.47%	8.44%	15.16%	-	-	-	-	-	-	-	28.16%
Index	-10.02%	-1.13%	8.74%	15.71%	-	-	-	-	-	-	-	28.60%

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investors shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. Returns are provided in USD. To the extent the base currency of an available share class is not USD, returns may increase or decrease as a result of currency fluctuations. For performance data current to the most recent month end, please visit www.kraneshares.eu.

Index returns are for illustrative purposes only. Index performance returns do not reflect any management fees, transaction costs or expenses. Indexes are unmanaged and one cannot invest directly in an index. This is a marketing communication. Please refer to the prospectus of the UCITS, the KIID and the PRIIP before making any final investment decisions. The tax treatment depends on the individual circumstances of each client and may be subject to change in the future.

Listings as of 31/Jul/2026	Ticker	Currency	Listing Date	SEDOL	ISIN
London Stock Exchange	KOIB LN	GBP	09/Oct/2025	BW5Y2M6	IE00006Z73N7
London Stock Exchange	KOID LN	USD	09/Oct/2025	BLDCL51	IE00006Z73N7
Borsa Italiana	KOID IM	EUR	16/Oct/2025	BVPW8S1	IE00006Z73N7
Deutsche Börse	KBOT GY	EUR	05/Jan/2026	BPTJ8H5	IE00006Z73N7

Sector Breakdown Data from Bloomberg as of 31/Jul/2026	%
Information Technology	42.98
Industrials	38.13
Consumer Discretionary	13.50
Materials	5.31

Growth of USD 10,000

Data as of 31/Jul/2026



The Growth of USD 10,000 chart reflects an initial investment of USD 10,000 in the Funds USD share class on the day prior to the selected time period and assumes reinvestment of dividends and capital gains. For the growth of USD 10,000 chart since inception, the initial investment of USD 10,000 is instead made on the inception date of the Fund. Fund expenses, including management fees and other expenses were deducted. The growth of a USD 10,000 investment in the fund is hypothetical and for illustration purposes only. Fund performance data used in this chart is based on Fund NAV and represents past performance. Past performance does not guarantee future results.

Important Notes

Carefully consider the Funds' investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Funds' full and summary prospectus, which may be obtained by visiting www.kraneshares.eu. Read the prospectus carefully before investing

Investing involves risk, including possible loss of principal. There can be no assurance that a Fund will achieve its stated objectives. The Funds are subject to political, social or economic instability within China which may cause decline in value. Fluctuations in currency of foreign countries may have an adverse effect to domestic currency values. Emerging markets involve heightened risk related to the same factors as well as increase volatility and lower trading volume.

Narrowly focused investments typically exhibit higher volatility. Humanoid and embedded intelligence technology companies often face high research and capital costs, resulting in variable profitability in a competitive market where products can quickly become obsolete. Their reliance on intellectual property makes them vulnerable to losses, while legal and regulatory changes can impact profitability. Defining these companies can be complex, and some may risk commercial failure. They are also affected by global scientific developments, leading to rapid obsolescence, and may be subject to government regulations. Many companies in which the Fund invests may not currently be profitable, with no guarantee of future success.

The Fund's assets are expected to be concentrated in a sector, industry, market, or group of concentrations to the extent that the Underlying Index has such concentrations. The securities or futures in that concentration could react similarly to market developments. Thus, the Fund is subject to loss due to adverse occurrences that affect that concentration.

Neither MerQube, Inc. nor any of its affiliates (collectively, "MerQube") is the issuer or producer of KOID and MerQube has no duties, responsibilities, or obligations to investors in KOID. The index underlying the KOID is a product of MerQube and has been licensed for use by Krane Funds Advisors, LLC and its affiliates. Such index is calculated using, among other things, market data or other information ("Input Data") from one or more sources (each such source, a "Data Provider"). MerQube® is a registered trademark of MerQube, Inc. These trademarks have been licensed for certain purposes by Krane Funds Advisors, LLC and its affiliates in its capacity as the issuer of the KOID. KOID is not sponsored, endorsed, sold or promoted by MerQube, any Data Provider, or any other third party, and none of such parties make any representation regarding the advisability of investing in securities generally or in KOID particularly, nor do they have any liability for any errors, omissions, or interruptions of the Input Data, MerQube Global Humanoid and Embodied Intelligence Index, or any associated data. Neither MerQube nor the Data Providers make any representation or warranty, express or implied, to the owners of the shares of KOID or to any member of the public, of any kind, including regarding the ability of the MerQube Global Humanoid and Embodied Intelligence Index to track market performance or any asset class. The MerQube Global Humanoid and Embodied Intelligence Index is determined, composed and calculated by MerQube without regard to Krane Funds Advisors, LLC and its affiliates or the KOID. MerQube and Data Providers have no obligation to take the needs of Krane Funds Advisors, LLC and its affiliates or the owners of KOID into consideration in determining, composing or calculating the MerQube Global Humanoid and Embodied Intelligence Index.

Neither MerQube nor any Data Provider is responsible for and have not participated in the determination of the prices or amount of KOID or the timing of the issuance or sale of KOID or in the determination or calculation of the equation by which KOID is to be converted into cash, surrendered or redeemed, as the case may be. MerQube and Data Providers have no obligation or liability in connection with the administration, marketing or trading of KOID. There is no assurance that investment products based on the MerQube Global Humanoid and Embodied Intelligence Index will accurately track index performance or provide positive investment returns. MerQube is not an investment advisor. Inclusion of a security within an index is not a recommendation by MerQube to buy, sell, or hold such security, nor is it considered to be investment advice.

NEITHER MERQUBE NOR ANY OTHER DATA PROVIDER GUARANTEES THE ADEQUACY, ACCURACY, TIMELINESS AND/OR THE COMPLETENESS OF THE MERQUBE GLOBAL HUMANOID AND EMBODIED INTELLIGENCE INDEX OR ANY DATA RELATED THERETO (INCLUDING DATA INPUTS) OR ANY COMMUNICATION WITH RESPECT THERETO. NEITHER MERQUBE NOR ANY OTHER DATA PROVIDERS SHALL BE SUBJECT TO ANY DAMAGES OR LIABILITY FOR ANY ERRORS, OMISSIONS, OR DELAYS THEREIN. MERQUBE AND ITS DATA PROVIDERS MAKE NO EXPRESS OR IMPLIED WARRANTIES, AND THEY EXPRESSLY DISCLAIM ALL WARRANTIES, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE OR AS TO RESULTS TO BE OBTAINED BY KRANE FUNDS ADVISORS, LLC AND ITS AFFILIATES, OWNERS OF THE KOID, OR ANY OTHER PERSON OR ENTITY FROM THE USE OF THE MERQUBE GLOBAL HUMANOID AND EMBODIED INTELLIGENCE INDEX OR WITH RESPECT TO ANY DATA RELATED THERETO. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT WHATSOEVER SHALL MERQUBE OR DATA PROVIDERS BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES INCLUDING BUT NOT LIMITED TO, LOSS OF PROFITS, TRADING LOSSES, LOST TIME OR GOODWILL, EVEN IF THEY HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, WHETHER IN CONTRACT, TORT, STRICT LIABILITY, OR OTHERWISE. THE FOREGOING REFERENCES TO "MERQUBE" AND/OR "DATA PROVIDER" SHALL BE CONSTRUED TO INCLUDE ANY AND ALL SERVICE PROVIDERS, CONTRACTORS, EMPLOYEES, AGENTS, AND AUTHORIZED REPRESENTATIVES OF THE REFERENCED PARTY.

This material is for information only and does not constitute an offer or recommendation to buy or sell any investment, or subscribe to any investment management or advisory service. It is not, under any circumstances, intended for distribution to the general public. You are accessing information which constitutes a financial promotion under section 21 of the Financial Services and Markets Act 2000 ("FSMA"). In relation to the United Kingdom, this information is only directed at, and may only be distributed to, persons who are "Investment Professionals" (being persons having professional experience in matters relating to investments) within the meaning of article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Financial Promotion Order"), persons to whom any of paragraphs (2)(a) to (d) of article 49 (high net worth companies, unincorporated associations etc.) of the financial promotion order apply, or persons to whom distribution may otherwise lawfully be made.

Any investment, and investment activity or controlled activity, to which this information relates is available only to such persons and will be engaged in only with such persons. Persons that do not have professional experience should not rely or act upon this information unless they are persons to whom any of paragraphs (2)(a) to (d) of article 49 apply to whom distribution of this information may otherwise lawfully be made.

In Switzerland, the Fund has appointed as Swiss Representative Waystone Fund Services (Switzerland) SA, Av. Villamont 17, 1005 Lausanne, Switzerland, Tel: +41 21 311 17 77, email: switzerland@waystone.com. The Fund's paying agent is Helvetische Bank AG. In respect of the Shares distributed in or from Switzerland, the place of performance and jurisdiction is Lausanne (Switzerland).

Although the information provided in this document has been obtained from sources which Krane Funds Advisors, LLC believes to be reliable, it does not guarantee accuracy of such information and such information may be incomplete or condensed. Krane Fund Advisors, LLC is appointed to act as investment manager in accordance with the requirements of the Central Bank. Krane Fund Advisors, LLC is appointed as the distributor of the ICAV. The Management Company may decide to terminate the agreements made for the marketing of the Fund in accordance with Article 93a of Directive 2009/65/EC.

The views and opinions expressed in this material are those of the authors Krane Fund Advisors. These opinions have been given in good faith but are subject to change without notice. It is the responsibility of the investor to evaluate the accuracy, completeness and usefulness of any opinions, advice, services, or other information provided.

This material may not be suitable for all investors. Any performance quoted represents past performance and is no guarantee of future results. Past performance is not indicative or a guarantee of future performance. Carefully consider the Funds' investment objectives, risk factors, charges and expenses before investing.

UCITS ETF's units / shares purchased on the secondary market cannot usually be sold directly back to UCITS ETF. Investors must buy and sell units / shares on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying units / shares and may receive less than the current net asset value when selling them.

UCITS shares are not individually redeemable with the issuing fund other than in large Creation Unit aggregations. In doing so, the investor may incur brokerage commissions and may pay more than net asset value (NAV) when buying and receive less than net asset value (NAV) when selling. The Net Asset Value per share is calculated in accordance with the "Determination of Net Asset Value" section of the prospectus, using the official closing price published by the relevant exchange. Shares are bought and sold at market price which may or may not be consistent with NAV.

This and additional information, including historical and the most recent month-end performance, can be found in the Fund Literature (Prospectus, Supplement, KIID, PRIIP), please visit www.waystone.com, or www.kraneshares.eu. The Fund's indicative net asset value (iNAV) can be obtained during trading hours at <https://www.londonstockexchange.com/stock/KOID/kraneshares-icav/company-page>. To view our Summary of Investor Rights, available in English, please visit www.kraneshares.eu or click here. KIID and PRIIP documents are available in the language of any Member State where such fund is distributed, and the prospectus is available only in English. [R-KS-EU]